{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":48,"searchCount":0},"additional":{"omics_type":["Unknown"],"volume":["24(3)"],"submitter":["Dubsky P"],"pubmed_abstract":["<h4>Background</h4>In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance of EPclin in relation to well-established clinical guidelines is assessed.<h4>Patients and methods</h4>We assigned risk groups to 1702 ER-positive/HER2-negative postmenopausal women from two large phase III trials treated only with endocrine therapy. Prognosis was assigned according to National Comprehensive Cancer Center Network-, German S3-, St Gallen guidelines and the EPclin. Prognostic groups were compared using the Kaplan-Meier survival analysis.<h4>Results</h4>After 10 years, absolute risk reductions (ARR) between the high- and low-risk groups ranged from 6.9% to 11.2% if assigned according to guidelines. It was at 18.7% for EPclin. EPclin reassigned 58%-61% of women classified as high-/intermediate-risk (according to clinical guidelines) to low risk. Women reclassified to low risk showed a 5% rate of distant metastasis at 10 years.<h4>Conclusion</h4>The EPclin score is able to predict favorable prognosis in a majority of patients that clinical guidelines would assign to intermediate or high risk. EPclin may reduce the indications for chemotherapy in ER-positive postmenopausal women with a limited number of clinical risk factors."],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pagination":["640-7"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3574544"],"repository":["biostudies-literature"],"pubmed_title":["EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer."],"pmcid":["PMC3574544"],"pubmed_authors":["Weber KE","Jakesz R","Mayr D","Austrian Breast and Colorectal Cancer Study Group (ABCSG)","Dubsky P","Brase JC","Greil R","Petry C","Bachner M","Schmidt M","Gehrmann MC","Kronenwett R","Rudas M","Filipits M","Sedivy R","Gnant M","Singer CF","Luisser I","Klug E","Dietze O"],"view_count":["48"],"additional_accession":[]},"is_claimable":false,"name":"EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.","description":"<h4>Background</h4>In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance of EPclin in relation to well-established clinical guidelines is assessed.<h4>Patients and methods</h4>We assigned risk groups to 1702 ER-positive/HER2-negative postmenopausal women from two large phase III trials treated only with endocrine therapy. Prognosis was assigned according to National Comprehensive Cancer Center Network-, German S3-, St Gallen guidelines and the EPclin. Prognostic groups were compared using the Kaplan-Meier survival analysis.<h4>Results</h4>After 10 years, absolute risk reductions (ARR) between the high- and low-risk groups ranged from 6.9% to 11.2% if assigned according to guidelines. It was at 18.7% for EPclin. EPclin reassigned 58%-61% of women classified as high-/intermediate-risk (according to clinical guidelines) to low risk. Women reclassified to low risk showed a 5% rate of distant metastasis at 10 years.<h4>Conclusion</h4>The EPclin score is able to predict favorable prognosis in a majority of patients that clinical guidelines would assign to intermediate or high risk. EPclin may reduce the indications for chemotherapy in ER-positive postmenopausal women with a limited number of clinical risk factors.","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Mar","modification":"2021-02-21T11:01:19Z","creation":"2019-03-27T01:04:54Z"},"accession":"S-EPMC3574544","cross_references":{"pubmed":["23035151"],"doi":["10.1093/annonc/mds334"]}}